

**As Reported by the Senate Medicaid, Health and Human Services  
Committee**

**130th General Assembly  
Regular Session  
2013-2014**

**Sub. H. B. No. 315**

**Representative Wachtmann**

**Cosponsors: Representatives Antonio, Bishoff, Adams, R., Amstutz,  
Anielski, Ashford, Baker, Barborak, Barnes, Beck, Blair, Blessing, Boose,  
Brown, Buchy, Burkley, Celebrezze, Cera, Conditt, Derickson, DeVitis,  
Driehaus, Duffey, Foley, Green, Grossman, Hackett, Hagan, R., Hall, Hayes,  
Henne, Hill, Huffman, Johnson, Kunze, Landis, Letson, Maag, McClain,  
Milkovich, O'Brien, Patmon, Patterson, Pelanda, Perales, Pillich, Ramos,  
Reece, Retherford, Rogers, Rosenberger, Ruhl, Sears, Sheehy, Slaby, Smith,  
Stautberg, Stebelton, Stinziano, Sykes, Thompson, Williams, Winburn,  
Young Speaker Batchelder**

—

**A B I L L**

To amend sections 3711.12 and 3719.41 and to enact 1  
sections 3711.13 and 3711.30 of the Revised Code 2  
to require reports to the Department of Health 3  
regarding newborns diagnosed as opioid dependent, 4  
to update the chemical name for a type of 5  
controlled substance, and to specify procedures 6  
for granting variances or waivers of any 7  
requirement in the rules governing operation of 8  
maternity homes. 9

**BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:**

**Section 1.** That sections 3711.12 and 3719.41 be amended and 10

sections 3711.13 and 3711.30 of the Revised Code be enacted to 11  
read as follows: 12

**Sec. 3711.12.** (A) The director of health shall adopt rules in 13  
accordance with Chapter 119. of the Revised Code as the director 14  
considers necessary to implement the requirements of this chapter 15  
for licensure and operation of maternity units, newborn care 16  
nurseries, and maternity homes. The rules shall include provisions 17  
for the following: 18

(1) Licensure application forms and procedures; 19

(2) Renewal procedures, including procedures that address the 20  
right of the director of health, at the director's sole 21  
discretion, to conduct an inspection prior to renewal of a 22  
license; 23

(3) Initial license fees and license renewal fees; 24

(4) Fees for inspections conducted by the director under 25  
section 3711.10 of the Revised Code; 26

(5) Safety standards, quality-of-care standards, and 27  
quality-of-care data reporting requirements; 28

(6) Reporting and auditing requirements; 29

(7) Inspection criteria, procedures, and guidelines; 30

(8) Application forms to be used and procedures to be 31  
followed in applying under section 3711.13 of the Revised Code for 32  
a variance or waiver of any of the requirements of the rules 33  
adopted under this section regarding the operation of a maternity 34  
home; 35

(9) Any other rules necessary to implement this chapter. 36

(B) When adopting rules under this section, the director 37  
shall give consideration to recommendations regarding obstetric 38

and newborn care issued by the American college of obstetricians 39  
and gynecologists; American academy of pediatrics; American 40  
academy of family physicians; American society of 41  
anesthesiologists; American college of nurse-midwives; United 42  
States centers for disease control and prevention; association of 43  
women's health, obstetric and neonatal nurses; and association of 44  
perioperative registered nurses, or their successor organizations. 45  
The director shall also consider the recommendations of the 46  
maternity and newborn advisory council established in section 47  
3711.20 of the Revised Code. 48

Sec. 3711.13. (A) A board of health may grant a variance from 49  
or waiver of any of the requirements established in rules adopted 50  
under section 3711.12 of the Revised Code regarding the operation 51  
of a maternity home. 52

(B) Each maternity home seeking a variance or waiver shall 53  
file an application with the board of health of the city or 54  
general health district in which the maternity home is located. 55  
The application shall be made on the form and in accordance with 56  
the procedures specified in rules adopted under section 3711.12 of 57  
the Revised Code. 58

(C) The board of health shall review all applications 59  
received. Not later than forty-five days after receiving an 60  
application, the board shall determine whether to grant the 61  
variance or waiver and shall notify the applicant in writing of 62  
the board's decision. 63

(D) Both of the following apply to a board of health in 64  
determining whether to grant a variance or waiver: 65

(1) A variance shall be granted to an applicant if the board 66  
determines that the intent of a requirement has been met by the 67  
applicant in an alternate manner. 68

(2) A waiver shall be granted if the board determines that 69  
strict application of a requirement would cause an undue hardship 70  
to the applicant and that granting the waiver would not jeopardize 71  
the health and safety of any patient or resident. 72

(E) If a board of health denies a variance or waiver 73  
requested by a maternity home, the home may appeal the denial by 74  
filing a notice of appeal with the director of health. The notice 75  
must be filed not later than thirty days after the board's denial 76  
of the request. 77

Not later than forty-five days after the notice of appeal is 78  
filed, the director shall either affirm the board's denial or 79  
grant the variance or waiver. The director shall notify the board 80  
and the maternity home in writing of the director's action. 81

(F) Notwithstanding any other provision of this section, the 82  
director may void the board's granting of a waiver or variance 83  
issued under this section. The director shall notify the board and 84  
the maternity home in writing of the director's action not later 85  
than forty-five days after the decision to void. 86

**Sec. 3711.30. (A) As used in this section, "opioid" means** 87  
**opium, opium derivatives, and synthetic opium substitutes.** 88

(B) Each maternity unit, newborn care nursery, and maternity 89  
home shall report to the department of health the number of 90  
newborns born to residents of this state in the unit, nursery, or 91  
home during the preceding calendar quarter that were diagnosed as 92  
opioid dependent at birth. The reports shall be submitted not 93  
later than thirty days after the end of each quarter and shall not 94  
include any patient-identifying information. 95

(C) The department shall establish standards and procedures 96  
for reporting the information required by this section. The 97  
information reported under this section shall not be used for law 98

enforcement purposes or disclosed to law enforcement authorities. 99

(D) The department shall compile the information submitted 100  
under this section and make a summary of that information 101  
available to the public not later than ninety days after the end 102  
of each calendar year. 103

**Sec. 3719.41.** Controlled substance schedules I, II, III, IV, 104  
and V are hereby established, which schedules include the 105  
following, subject to amendment pursuant to section 3719.43 or 106  
3719.44 of the Revised Code. 107

SCHEDULE I 108

(A) Narcotics-opiates 109

Any of the following opiates, including their isomers, 110  
esters, ethers, salts, and salts of isomers, esters, and ethers, 111  
unless specifically excepted under federal drug abuse control 112  
laws, whenever the existence of these isomers, esters, ethers, and 113  
salts is possible within the specific chemical designation: 114

(1) Acetyl-alpha-methylfentanyl 115  
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); 116

(2) Acetylmethadol; 117

(3) Allylprodine; 118

(4) Alphacetylmethadol (except levo-alphacetylmethadol, also 119  
known as levo-alpha-acetylmethadol, levomethadyl acetate, or 120  
LAAM); 121

(5) Alphameprodine; 122

(6) Alphamethadol; 123

(7) Alpha-methylfentanyl 124  
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 125  
1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine); 126

(8) Alpha-methylthiofentanyl 127

(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);	128
	129
(9) Benzethidine;	130
(10) Betacetylmethadol;	131
(11) Beta-hydroxyfentanyl	132
(N-[1-(2-hydroxy-2-phenethyl-4-piperidinyl]-N-phenylpropanamide);	133
(12) Beta-hydroxy-3-methylfentanyl (other name:	134
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);	135
	136
(13) Betameprodine;	137
(14) Betamethadol;	138
(15) Betaprodine;	139
(16) Clonitazene;	140
(17) Dextromoramide;	141
(18) Diampromide;	142
(19) Diethylthiambutene;	143
(20) Difenoxin;	144
(21) Dimenoxadol;	145
(22) Dimepheptanol;	146
(23) Dimethylthiambutene;	147
(24) Dioxaphetyl butyrate;	148
(25) Dipipanone;	149
(26) Ethylmethylthiambutene;	150
(27) Etonitazene;	151
(28) Etoxeridine;	152
(29) Furethidine;	153

(30) Hydroxypethidine;	154
(31) Ketobemidone;	155
(32) Levomoramide;	156
(33) Levophenacylmorphane;	157
(34) 3-methylfentanyl	158
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);	159
(35) 3-methylthiofentanyl	160
(N-[3-methyl-1-[2-(thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide);	161
(36) Morpheridine;	162
(37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);	163
(38) Noracymethadol;	164
(39) Norlevorphanol;	165
(40) Normethadone;	166
(41) Norpipanone;	167
(42) Para-fluorofentanyl	168
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide;	169
(43) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);	170
(44) Phenadoxone;	171
(45) Phenampromide;	172
(46) Phenomorphan;	173
(47) Phenoperidine;	174
(48) Piritramide;	175
(49) Proheptazine;	176
(50) Properidine;	177
(51) Propiram;	178
	179

(52) Racemoramide;	180
(53) Thiofentanyl	181
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide;	182
(54) Tilidine;	183
(55) Trimeperidine.	184
(B) Narcotics-opium derivatives	185
Any of the following opium derivatives, including their	186
salts, isomers, and salts of isomers, unless specifically excepted	187
under federal drug abuse control laws, whenever the existence of	188
these salts, isomers, and salts of isomers is possible within the	189
specific chemical designation:	190
(1) Acetorphine;	191
(2) Acetyldihydrocodeine;	192
(3) Benzylmorphine;	193
(4) Codeine methylbromide;	194
(5) Codeine-n-oxide;	195
(6) Cyprenorphine;	196
(7) Desomorphine;	197
(8) Dihydromorphine;	198
(9) Drotebanol;	199
(10) Etorphine (except hydrochloride salt);	200
(11) Heroin;	201
(12) Hydromorphenol;	202
(13) Methyldesorphine;	203
(14) Methyldihydromorphine;	204
(15) Morphine methylbromide;	205
(16) Morphine methylsulfonate;	206

(17) Morphine-n-oxide;	207
(18) Myrophine;	208
(19) Nicocodeine;	209
(20) Nicomorphine;	210
(21) Normorphine;	211
(22) Pholcodine;	212
(23) Thebacon.	213
(C) Hallucinogens	214
Any material, compound, mixture, or preparation that contains	215
any quantity of the following hallucinogenic substances, including	216
their salts, isomers, and salts of isomers, unless specifically	217
excepted under federal drug abuse control laws, whenever the	218
existence of these salts, isomers, and salts of isomers is	219
possible within the specific chemical designation. For the	220
purposes of this division only, "isomer" includes the optical	221
isomers, position isomers, and geometric isomers.	222
(1) Alpha-ethyltryptamine (some trade or other names:	223
etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine;	224
3-(2-aminobutyl) indole; alpha-ET; and AET);	225
(2) 4-bromo-2,5-dimethoxyamphetamine (some trade or other	226
names: 4-bromo-2,5-dimethoxy-alpha-methyphenethylamine;	227
4-bromo-2,5-DMA);	228
(3) 4-bromo-2,5-dimethoxyphenethylamine (some trade or other	229
names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;	230
alpha-desmethyl DOB; 2C-B, Nexus);	231
(4) 2,5-dimethoxyamphetamine (some trade or other names:	232
2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);	233
(5) 2,5-dimethoxy-4-ethylamphetamine (some trade or other	234
names: DOET);	235

(6) 4-methoxyamphetamine (some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; PMA);	236 237 238
(7) 5-methoxy-3,4-methylenedioxy-amphetamine;	239
(8) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM" and "STP");	240 241 242
(9) 3,4-methylenedioxy amphetamine (MDA);	243
(10) 3,4-methylenedioxymethamphetamine (MDMA);	244
(11) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);	245 246 247
(12) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);	248 249 250
(13) 3,4,5-trimethoxy amphetamine;	251
(14) Bufotenine (some trade or other names: 3-(beta-dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N, N-dimethyltryptamine; mappine);	252 253 254 255
(15) Diethyltryptamine (some trade or other names: N, N-diethyltryptamine; DET);	256 257
(16) Dimethyltryptamine (some trade or other names: DMT);	258
(17) Ibogaine (some trade or other names: 7-ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano- 5H-pyrido[1',2':1,2] azepino [5, 4-b] indole; tabernanthe iboga);	259 260 261
(18) Lysergic acid diethylamide;	262
(19) Marihuana;	263
(20) Mescaline;	264

(21) Parahexyl (some trade or other names: 3-hexyl-1-	265
hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;	266
synhexyl);	267
(22) Peyote (meaning all parts of the plant presently	268
classified botanically as "Lophophora williamsii Lemaire," whether	269
growing or not, the seeds of that plant, any extract from any part	270
of that plant, and every compound, manufacture, salts, derivative,	271
mixture, or preparation of that plant, its seeds, or its	272
extracts);	273
(23) N-ethyl-3-piperidyl benzilate;	274
(24) N-methyl-3-piperidyl benzilate;	275
(25) Psilocybin;	276
(26) Psilocyn;	277
(27) Tetrahydrocannabinols (synthetic equivalents of the	278
substances contained in the plant, or in the resinous extractives	279
of Cannabis, sp. and/or synthetic substances, derivatives, and	280
their isomers with similar chemical structure and pharmacological	281
activity such as the following: delta-1-cis or trans	282
tetrahydrocannabinol, and their optical isomers; delta-6-cis or	283
trans tetrahydrocannabinol, and their optical isomers;	284
delta-3,4-cis or trans tetrahydrocannabinol, and its optical	285
isomers. (Since nomenclature of these substances is not	286
internationally standardized, compounds of these structures,	287
regardless of numerical designation of atomic positions, are	288
covered.));	289
(28) Ethylamine analog of phencyclidine (some trade or other	290
names: N-ethyl-1-phenylcyclohexylamine;	291
(1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;	292
cyclohexamine; PCE);	293
(29) Pyrrolidine analog of phencyclidine (some trade or other	294

names: 1-(1-phenylcyclohexyl)pyrrolidine; PCPy; PHP);	295
(30) Thiophene analog of phencyclidine (some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thienyl analog of phencyclidine; TPCP; TCP);	296 297 298
(31) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;	299
(32) Hashish;	300
(33) Salvia divinorum;	301
(34) Salvinorin A;	302
(35)	303
(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);	304 305
(36) 1-pentyl-3-(1-adamantoyl)indole (AB-001);	306
(37) N-adamantyl-1-pentylindole-3-carboxamide;	307
(38) N-adamantyl-1-pentylindazole-3-carboxamide (AKB48);	308
(39) 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone (methoxetamine);	309 310
(40) N,N-diallyl-5-methoxytryptamine (5MeO-DALT);	311
(41)	312
[1-(5-fluoropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoropentyl-UR-144; XLR11);	313 314
(42)	315
[1-(5-chloropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone (5-chloropentyl-UR-144);	316 317
(43)	318
[1-(5-bromopentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone (5-bromopentyl-UR-144);	319 320
(44)	321
{1-[2-(4-morpholinyl)ethyl]indol-3-yl}-(2,2,3,3-tetramethylcyclopropyl)	322

methanone (A-796,260);	323
(45)	324
1-[(N-methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole	325
(AM1248);	326
(46) N-adamantyl-1-(5-fluoropentylindole)-3-carboxamide;	327
(47) 5-(2-aminopropyl)benzofuran (5-APB);	328
(48) 6-(2-aminopropyl)benzofuran (6-APB);	329
(49) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB);	330
(50) 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB);	331
(51) Benzothiophenylcyclohexylpiperidine (BTCP);	332
(52) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);	333
(53) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);	334
(54) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);	335
(55) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);	336
(56) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine	337
(2C-T-2);	338
(57) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine	339
(2C-T-4);	340
(58) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);	341
(59) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);	342
(60) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);	343
(61) 4-methoxymethamphetamine (PMMA);	344
(62) 5,6 - Methylenedioxy-2-aminoindane (MDAI);	345
(63) 5-iodo-2-aminoindane (5-IAI);	346
(64) 2-(4-iodo-2,5-dimethoxyphenyl)-N-	347
[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe);	348
(65) Diphenylprolinol (diphenyl(pyrrolidin-2-yl)methanol,	349

D2PM);	350
(66) Desoxypipradrol (2-benzhydrylpiperidine);	351
(67) Synthetic cannabinoids - unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of a synthetic cannabinoid found to be in any of the following chemical groups or any of those groups which contain any synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical groups:	352 353 354 355 356 357 358 359
(a) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted on the indole ring to any extent or whether or not substituted on the naphthyl group to any extent. Naphthoylindoles include, but are not limited to, 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201), 1-pentyl-3-(1-naphthoyl)indole (JWH-018), and 1-butyl-3-(1-naphthoyl)indole (JWH-073).	360 361 362 363 364 365 366 367 368 369 370 371 372 373
(b) Naphthylmethylindoles: any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted on the indole ring to any	374 375 376 377 378 379 380 381

extent or whether or not substituted on the naphthyl group to any 382  
extent. Naphthylmethylindoles include, but are not limited to, 383  
(1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175). 384

(c) Naphthoylpyrroles: any compound containing a 385  
3-(1-naphthoyl)pyrrole structure with or without substitution at 386  
the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 387  
alkenyl, cycloalkylmethyl, cycloalkylethyl, 388  
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, 389  
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, 390  
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, 391  
whether or not further substituted on the pyrrole ring to any 392  
extent or whether or not substituted on the naphthyl group to any 393  
extent. Naphthoylpyrroles include, but are not limited to, 394  
1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147). 395

(d) Naphthylmethylindenes: any compound containing a 396  
naphthylmethylideneindene structure with or without substitution 397  
at the 3-position of the indene ring by an alkyl, haloalkyl, 398  
alkenyl, cycloalkylmethyl, cycloalkylethyl, 399  
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, 400  
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, 401  
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, 402  
whether or not further substituted on the indene group to any 403  
extent or whether or not substituted on the naphthyl group to any 404  
extent. Naphthylmethylindenes include, but are not limited to, 405  
(1-[(3-pentyl)-1H-inden-1-ylidene)methyl]naphthalene (JWH-176). 406

(e) Phenylacetylindoles: any compound containing a 407  
3-phenylacetylindole structure with or without substitution at the 408  
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, 409  
cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 410  
cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, 411  
(tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, or 412  
2-(4-morpholinyl)ethyl group, whether or not further substituted 413

on the indole ring to any extent or whether or not substituted on 414  
the phenyl group to any extent. Phenylacetylindoles include, but 415  
are not limited to, 1-pentyl-3-(2-methoxyphenylacetyl)indole 416  
(JWH-250), and 417  
1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8); 418  
1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203). 419

(f) Cyclohexylphenols: any compound containing a 420  
2-(3-hydroxycyclohexyl)phenol structure with or without 421  
substitution at the 5-position of the phenolic ring by an alkyl, 422  
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 423  
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, 424  
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, 425  
(N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, 426  
whether or not further substituted on the cyclohexyl group to any 427  
extent. Cyclohexylphenols include, but are not limited to, 428  
5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 429  
(some trade or other names: CP-47,497) and 430  
5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (some 431  
trade or other names: cannabicyclohexanol; CP-47,497 C8 432  
homologue). 433

(g) Benzoylindoles: any compound containing a 3-(~~1-naphthyl~~ 434  
1-benzoyl)indole structure with or without substitution at the 435  
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, 436  
cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 437  
cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, 438  
(tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl or 439  
2-(4-morpholinyl)ethyl group, whether or not further substituted 440  
on the indole ring to any extent or whether or not substituted on 441  
the phenyl group to any extent. Benzoylindoles include, but are 442  
not limited to, 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4), 443  
1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole 444  
(Pravadoline or WIN 48, 098). 445

(D) Depressants	446
Any material, compound, mixture, or preparation that contains	447
any quantity of the following substances having a depressant	448
effect on the central nervous system, including their salts,	449
isomers, and salts of isomers, unless specifically excepted under	450
federal drug abuse control laws, whenever the existence of these	451
salts, isomers, and salts of isomers is possible within the	452
specific chemical designation:	453
(1) Mecloqualone;	454
(2) Methaqualone.	455
(E) Stimulants	456
Unless specifically excepted or unless listed in another	457
schedule, any material, compound, mixture, or preparation that	458
contains any quantity of the following substances having a	459
stimulant effect on the central nervous system, including their	460
salts, isomers, and salts of isomers:	461
(1) Aminorex (some other names: aminoxaphen;	462
2-amino-5-phenyl-2-oxazoline; or	463
4,5-dihydro-5-phenyl-2-oxazolamine);	464
(2) Fenethylline;	465
(3) (+/-)cis-4-methylaminorex	466
((+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);	467
(4) N-ethylamphetamine;	468
(5) N,N-dimethylamphetamine (also known as	469
N,N-alpha-trimethyl-benzeneethanamine;	470
N,N-alpha-trimethylphenethylamine);	471
(6) N-methyl-1-(thiophen-2-yl) propan-2-amine	472
(Methiopropamine);	473
(7) Substituted cathinones - any compound except bupropion or	474

compounds listed under a different schedule, structurally derived 475  
from 2-aminopropan-1-one by substitution at the 1-position with 476  
either phenyl, naphthyl, or thiophene ring systems, whether or not 477  
the compound is further modified in any of the following ways: 478

(a) By substitution in the ring system to any extent with 479  
alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide 480  
substituents, whether or not further substituted in the ring 481  
system by one or more other univalent substituents; 482

(b) By substitution at the 3-position with an acyclic alkyl 483  
substituent; 484

(c) By substitution at the 2-amino nitrogen atom with alkyl, 485  
dialkyl, benzyl, or methoxybenzyl groups; 486

(d) By inclusion of the 2-amino nitrogen atom in a cyclic 487  
structure. 488

Examples of substituted cathinones include, but are not 489  
limited to, methyldone (3,4-methylenedioxy-methcathinone), MDPV 490  
(3,4-methylenedioxy-pyrovalerone), mephedrone 491  
(4-methylmethcathinone), 4-methoxymethcathinone, 492  
4-fluoromethcathinone, 3-fluoromethcathinone, Pentadrone 493  
(2-(methylamino)-1-phenyl-1-pentanone), pentylone 494  
(1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-pentanone), 495  
2-(1-pyrrolidinyl)-1-(4-methylphenyl)-1-propanone, alpha-PVP 496  
(1-phenyl-2-(1-pyrrolidinyl)-1-pentanone), cathinone 497  
(2-amino-1-phenyl-1-propanone), and methcathinone 498  
(2-(methylamino)-propiofenone). 499

SCHEDULE II 500

(A) Narcotics-opium and opium derivatives 501

Unless specifically excepted under federal drug abuse control 502  
laws or unless listed in another schedule, any of the following 503  
substances whether produced directly or indirectly by extraction 504  
from substances of vegetable origin, independently by means of 505

chemical synthesis, or by a combination of extraction and chemical synthesis:	506
	507
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following:	508
	509
	510
	511
	512
(a) Raw opium;	513
(b) Opium extracts;	514
(c) Opium fluid extracts;	515
(d) Powdered opium;	516
(e) Granulated opium;	517
(f) Tincture of opium;	518
(g) Codeine;	519
(h) Ethylmorphine;	520
(i) Etorphine hydrochloride;	521
(j) Hydrocodone;	522
(k) Hydromorphone;	523
(l) Metopon;	524
(m) Morphine;	525
(n) Oxycodone;	526
(o) Oxymorphone;	527
(p) Thebaine.	528
(2) Any salt, compound, derivative, or preparation thereof that is chemically equivalent to or identical with any of the substances referred to in division (A)(1) of this schedule, except that these substances shall not include the isoquinoline alkaloids	529
	530
	531
	532

of opium;	533
(3) Opium poppy and poppy straw;	534
(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves (including cocaine and ecgonine, their salts, isomers, and derivatives, and salts of those isomers and derivatives), and any salt, compound, derivative, or preparation thereof that is chemically equivalent to or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine;	535 536 537 538 539 540 541 542
(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy).	543 544 545
(B) Narcotics-opiates	546
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, but excluding dextrorphan and levopropoxyphene:	547 548 549 550 551 552 553
(1) Alfentanil;	554
(2) Alphaprodine;	555
(3) Anileridine;	556
(4) Bezitramide;	557
(5) Bulk dextropropoxyphene (non-dosage forms);	558
(6) Carfentanil;	559
(7) Dihydrocodeine;	560
(8) Diphenoxylate;	561

(9) Fentanyl;	562
(10) Isomethadone;	563
(11) Levo-alpha-acetylmethadol (some other names: levo-alpha-acetylmethadol; levomethadyl acetate; LAAM);	564 565
(12) Levomethorphan;	566
(13) Levorphanol;	567
(14) Metazocine;	568
(15) Methadone;	569
(16) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane;	570 571
(17) Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;	572 573
(18) Pethidine (meperidine);	574
(19) Pethidine-intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;	575 576
(20) Pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;	577 578
(21) Pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;	579 580
(22) Phenazocine;	581
(23) Piminodine;	582
(24) Racemethorphan;	583
(25) Racemorphan;	584
(26) Remifentanil;	585
(27) Sufentanil.	586
(C) Stimulants	587
Unless specifically excepted under federal drug abuse control	588

laws or unless listed in another schedule, any material, compound, 589  
mixture, or preparation that contains any quantity of the 590  
following substances having a stimulant effect on the central 591  
nervous system: 592

(1) Amphetamine, its salts, its optical isomers, and salts of 593  
its optical isomers; 594

(2) Methamphetamine, its salts, its isomers, and salts of its 595  
isomers; 596

(3) Methylphenidate; 597

(4) Phenmetrazine and its salts. 598

(D) Depressants 599

Unless specifically excepted under federal drug abuse control 600  
laws or unless listed in another schedule, any material, compound, 601  
mixture, or preparation that contains any quantity of the 602  
following substances having a depressant effect on the central 603  
nervous system, including their salts, isomers, and salts of 604  
isomers, whenever the existence of these salts, isomers, and salts 605  
of isomers is possible within the specific chemical designation: 606

(1) Amobarbital; 607

(2) Gamma-hydroxy-butyrate; 608

(3) Glutethimide; 609

(4) Pentobarbital; 610

(5) Phencyclidine (some trade or other names: 611  
1-(1-phenylcyclohexyl)piperidine; PCP); 612

(6) Secobarbital; 613

(7) 1-aminophenylcyclohexane and all N-mono-substituted 614  
and/or all N-N-disubstituted analogs including, but not limited 615  
to, the following: 616

(a) 1-phenylcyclohexylamine; 617

(b) (1-phenylcyclohexyl) methylamine;	618
(c) (1-phenylcyclohexyl) dimethylamine;	619
(d) (1-phenylcyclohexyl) methylethylamine;	620
(e) (1-phenylcyclohexyl) isopropylamine;	621
(f) 1-(1-phenylcyclohexyl) morpholine.	622
(E) Hallucinogenic substances	623
(1) Nabilone (another name for nabilone:	624
(+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-	625
hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one).	626
(F) Immediate precursors	627
Unless specifically excepted under federal drug abuse control	628
laws or unless listed in another schedule, any material, compound,	629
mixture, or preparation that contains any quantity of the	630
following substances:	631
(1) Immediate precursor to amphetamine and methamphetamine:	632
(a) Phenylacetone (some trade or other names:	633
phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl	634
ketone);	635
(2) Immediate precursors to phencyclidine (PCP):	636
(a) 1-phenylcyclohexylamine;	637
(b) 1-piperidinocyclohexanecarbonitrile (PCC).	638
SCHEDULE III	639
(A) Stimulants	640
Unless specifically excepted under federal drug abuse control	641
laws or unless listed in another schedule, any material, compound,	642
mixture, or preparation that contains any quantity of the	643
following substances having a stimulant effect on the central	644
nervous system, including their salts, their optical isomers,	645

position isomers, or geometric isomers, and salts of these 646  
isomers, whenever the existence of these salts, isomers, and salts 647  
of isomers is possible within the specific chemical designation: 648

(1) All stimulant compounds, mixtures, and preparations 649  
included in schedule III pursuant to the federal drug abuse 650  
control laws and regulations adopted under those laws; 651

(2) Benzphetamine; 652

(3) Chlorphentermine; 653

(4) Clortermine; 654

(5) Phendimetrazine. 655

(B) Depressants 656

Unless specifically excepted under federal drug abuse control 657  
laws or unless listed in another schedule, any material, compound, 658  
mixture, or preparation that contains any quantity of the 659  
following substances having a depressant effect on the central 660  
nervous system: 661

(1) Any compound, mixture, or preparation containing 662  
amobarbital, secobarbital, pentobarbital, or any salt of any of 663  
these drugs, and one or more other active medicinal ingredients 664  
that are not listed in any schedule; 665

(2) Any suppository dosage form containing amobarbital, 666  
secobarbital, pentobarbital, or any salt of any of these drugs and 667  
approved by the food and drug administration for marketing only as 668  
a suppository; 669

(3) Any substance that contains any quantity of a derivative 670  
of barbituric acid or any salt of a derivative of barbituric acid; 671

(4) Chlorhexadol; 672

(5) Ketamine, its salts, isomers, and salts of isomers (some 673  
other names for ketamine: 674

(+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone);	675
(6) Lysergic acid;	676
(7) Lysergic acid amide;	677
(8) Methyprylon;	678
(9) Sulfondiethylmethane;	679
(10) Sulfonethylmethane;	680
(11) Sulfonmethane;	681
(12) Tiletamine, zolazepam, or any salt of tiletamine or zolazepam (some trade or other names for a tiletamine-zolazepam combination product: Telazol); (some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone); (some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8- dihydro-1,3,8-trimethylpyrazolo-[3, 4-e][1,4]-diazepin-7(1H)-one; flupyrazapon).	682 683 684 685 686 687 688
(C) Narcotic antidotes	689
(1) Nalorphine.	690
(D) Narcotics-narcotic preparations	691
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:	692 693 694 695 696
(1) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;	697 698 699
(2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;	700 701 702
(3) Not more than 300 milligrams of dihydrocodeinone per 100	703

milliliters or not more than 15 milligrams per dosage unit, with a 704  
fourfold or greater quantity of an isoquinoline alkaloid of opium; 705

(4) Not more than 300 milligrams of dihydrocodeinone per 100 706  
milliliters or not more than 15 milligrams per dosage unit, with 707  
one or more active, nonnarcotic ingredients in recognized 708  
therapeutic amounts; 709

(5) Not more than 1.8 grams of dihydrocodeine per 100 710  
milliliters or not more than 90 milligrams per dosage unit, with 711  
one or more active, nonnarcotic ingredients in recognized 712  
therapeutic amounts; 713

(6) Not more than 300 milligrams of ethylmorphine per 100 714  
milliliters or not more than 15 milligrams per dosage unit, with 715  
one or more active, nonnarcotic ingredients in recognized 716  
therapeutic amounts; 717

(7) Not more than 500 milligrams of opium per 100 milliliters 718  
or per 100 grams or not more than 25 milligrams per dosage unit, 719  
with one or more active, nonnarcotic ingredients in recognized 720  
therapeutic amounts; 721

(8) Not more than 50 milligrams of morphine per 100 722  
milliliters or per 100 grams, with one or more active, nonnarcotic 723  
ingredients in recognized therapeutic amounts. 724

(E) Anabolic steroids 725

Unless specifically excepted under federal drug abuse control 726  
laws or unless listed in another schedule, any material, compound, 727  
mixture, or preparation that contains any quantity of the 728  
following substances, including their salts, esters, isomers, and 729  
salts of esters and isomers, whenever the existence of these 730  
salts, esters, and isomers is possible within the specific 731  
chemical designation: 732

(1) Anabolic steroids. Except as otherwise provided in 733

division (E)(1) of schedule III, "anabolic steroids" means any 734  
drug or hormonal substance that is chemically and 735  
pharmacologically related to testosterone (other than estrogens, 736  
progestins, and corticosteroids) and that promotes muscle growth. 737  
"Anabolic steroids" does not include an anabolic steroid that is 738  
expressly intended for administration through implants to cattle 739  
or other nonhuman species and that has been approved by the United 740  
States secretary of health and human services for that 741  
administration, unless a person prescribes, dispenses, or 742  
distributes this type of anabolic steroid for human use. "Anabolic 743  
steroid" includes, but is not limited to, the following: 744

- (a) Boldenone; 745
- (b) Chlorotestosterone (4-chlortestosterone); 746
- (c) Clostebol; 747
- (d) Dehydrochlormethyltestosterone; 748
- (e) Dihydrotestosterone (4-dihydrotestosterone); 749
- (f) Drostanolone; 750
- (g) Ethylestrenol; 751
- (h) Fluoxymesterone; 752
- (i) Formebolone (formebolone); 753
- (j) Mesterolone; 754
- (k) Methandienone; 755
- (l) Methandranone; 756
- (m) Methandriol; 757
- (n) Methandrostenolone; 758
- (o) Methenolone; 759
- (p) Methyltestosterone; 760
- (q) Mibolerone; 761

(r) Nandrolone;	762
(s) Norethandrolone;	763
(t) Oxandrolone;	764
(u) Oxymesterone;	765
(v) Oxymetholone;	766
(w) Stanolone;	767
(x) Stanozolol;	768
(y) Testolactone;	769
(z) Testosterone;	770
(aa) Trenbolone;	771
(bb) Any salt, ester, isomer, or salt of an ester or isomer of a drug or hormonal substance described or listed in division (E)(1) of schedule III if the salt, ester, or isomer promotes muscle growth.	772 773 774 775
(F) Hallucinogenic substances	776
(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved drug product (some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- 6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol).	777 778 779 780 781 782
SCHEDULE IV	783
(A) Narcotic drugs	784
Unless specifically excepted by federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:	785 786 787 788 789

(1) Not more than one milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;	790 791
(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane)[final dosage forms].	792 793 794
(B) Depressants	795
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:	796 797 798 799 800 801
(1) Alprazolam;	802
(2) Barbital;	803
(3) Bromazepam;	804
(4) Camazepam;	805
(5) Chloral betaine;	806
(6) Chloral hydrate;	807
(7) Chlordiazepoxide;	808
(8) Clobazam;	809
(9) Clonazepam;	810
(10) Clorazepate;	811
(11) Clotiazepam;	812
(12) Cloxazolam;	813
(13) Delorazepam;	814
(14) Diazepam;	815
(15) Estazolam;	816

(16) Ethchlorvynol;	817
(17) Ethinamate;	818
(18) Ethyl loflazepate;	819
(19) Fludiazepam;	820
(20) Flunitrazepam;	821
(21) Flurazepam;	822
(22) Halazepam;	823
(23) Haloxazolam;	824
(24) Ketazolam;	825
(25) Loprazolam;	826
(26) Lorazepam;	827
(27) Lormetazepam;	828
(28) Mebutamate;	829
(29) Medazepam;	830
(30) Meprobamate;	831
(31) Methohexital;	832
(32) Methylphenobarbital (mephobarbital);	833
(33) Midazolam;	834
(34) Nimetazepam;	835
(35) Nitrazepam;	836
(36) Nordiazepam;	837
(37) Oxazepam;	838
(38) Oxazolam;	839
(39) Paraldehyde;	840
(40) Petrichloral;	841

(41) Phenobarbital;	842
(42) Pinazepam;	843
(43) Prazepam;	844
(44) Quazepam;	845
(45) Temazepam;	846
(46) Tetrazepam;	847
(47) Triazolam;	848
(48) Zaleplon;	849
(49) Zolpidem.	850
(C) Fenfluramine	851

Any material, compound, mixture, or preparation that contains 852  
any quantity of the following substances, including their salts, 853  
their optical isomers, position isomers, or geometric isomers, and 854  
salts of these isomers, whenever the existence of these salts, 855  
isomers, and salts of isomers is possible within the specific 856  
chemical designation: 857

(1) Fenfluramine. 858

(D) Stimulants 859

Unless specifically excepted under federal drug abuse control 860  
laws or unless listed in another schedule, any material, compound, 861  
mixture, or preparation that contains any quantity of the 862  
following substances having a stimulant effect on the central 863  
nervous system, including their salts, their optical isomers, 864  
position isomers, or geometric isomers, and salts of these 865  
isomers, whenever the existence of these salts, isomers, and salts 866  
of isomers is possible within the specific chemical designation: 867

(1) Cathine ((+)-norpseudoephedrine); 868

(2) Diethylpropion; 869

(3) Fencamfamin;	870
(4) Fenproporex;	871
(5) Mazindol;	872
(6) Mefenorex;	873
(7) Modafinil;	874
(8) Pemoline (including organometallic complexes and chelates thereof);	875 876
(9) Phentermine;	877
(10) Pipradrol;	878
(11) Sibutramine;	879
(12) SPA [(-)-1-dimethylamino-1,2-diphenylethane].	880
(E) Other substances	881
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including their salts:	882 883 884 885
(1) Pentazocine;	886
(2) Butorphanol (including its optical isomers).	887
SCHEDULE V	888
(A) Narcotic drugs	889
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any of the following narcotic drugs, and their salts, as set forth below:	890 891 892 893
(1) Buprenorphine.	894
(B) Narcotics-narcotic preparations	895
Narcotic drugs containing non-narcotic active medicinal	896

ingredients. Any compound, mixture, or preparation that contains 897  
any of the following narcotic drugs, or their salts calculated as 898  
the free anhydrous base or alkaloid, in limited quantities as set 899  
forth below, and that includes one or more nonnarcotic active 900  
medicinal ingredients in sufficient proportion to confer upon the 901  
compound, mixture, or preparation valuable medicinal qualities 902  
other than those possessed by narcotic drugs alone: 903

(1) Not more than 200 milligrams of codeine per 100 904  
milliliters or per 100 grams; 905

(2) Not more than 100 milligrams of dihydrocodeine per 100 906  
milliliters or per 100 grams; 907

(3) Not more than 100 milligrams of ethylmorphine per 100 908  
milliliters or per 100 grams; 909

(4) Not more than 2.5 milligrams of diphenoxylate and not 910  
less than 25 micrograms of atropine sulfate per dosage unit; 911

(5) Not more than 100 milligrams of opium per 100 milliliters 912  
or per 100 grams; 913

(6) Not more than 0.5 milligram of difenoxin and not less 914  
than 25 micrograms of atropine sulfate per dosage unit. 915

(C) Stimulants 916

Unless specifically exempted or excluded under federal drug 917  
abuse control laws or unless listed in another schedule, any 918  
material, compound, mixture, or preparation that contains any 919  
quantity of the following substances having a stimulant effect on 920  
the central nervous system, including their salts, isomers, and 921  
salts of isomers: 922

(1) Ephedrine, except as provided in division (K) of section 923  
3719.44 of the Revised Code; 924

(2) Pyrovalerone. 925

**Section 2.** That existing sections 3711.12 and 3719.41 of the 926

Revised Code are hereby repealed.

927